Status:
UNKNOWN
Intravenous Immunoglobulin (IVIG) for Resistant Neuropathic Pain
Lead Sponsor:
University of Calgary
Conditions:
Neuropathic Pain
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This project addresses a vexing problem that has alluded the best efforts of the medical/scientific community: treatment of resistant neuropathic pain. Neuropathic pain is common and includes conditio...
Detailed Description
This study will employ a randomized double blind cross-over design. A total of 12 subjects will be recruited for the study. Once each subject has satisfied the inclusion and exclusion criteria and pro...
Eligibility Criteria
Inclusion
- Age \>18 years; Clinical diagnosis of treatment-resistant neuropathic pain;
- Score of 4/10 or greater on the DN4 NeP screening questionnaire;
- Bedside examination confirming symptoms of neuropathic pain;
- Moderate to severe pain;
- Completed adequate analgesic trials according to neuropathic pain clinical practice guidelines;
- provides informed consent
Exclusion
- Pregnant or lactating women;
- Clinical diagnosis of phantom limb pain;
- History of psychosis;
- current, substance dependency disorder;
- presence of clinically significant cardiac or pulmonary disorder that would compromise participants' safety;
- severe pain disorder other than the chronic NeP under study;
- Abnormalities above 1.5 times upper range of normal on screening CBC, blood chemistry;
- Serum IgA less than \<0.05 g/L
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2010
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00850005
Start Date
February 1 2009
End Date
December 1 2010
Last Update
February 24 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Foothills Medical Centre
Calgary, Alberta, Canada